博碩士論文 110223041 完整後設資料紀錄

DC 欄位 語言
DC.contributor化學學系zh_TW
DC.creator李東zh_TW
DC.creatorDong Lien_US
dc.date.accessioned2023-8-14T07:39:07Z
dc.date.available2023-8-14T07:39:07Z
dc.date.issued2023
dc.identifier.urihttp://ir.lib.ncu.edu.tw:88/thesis/view_etd.asp?URN=110223041
dc.contributor.department化學學系zh_TW
DC.description國立中央大學zh_TW
DC.descriptionNational Central Universityen_US
dc.description.abstract癌症為全球死因第二位,每年約有一千萬人死於癌症。而在台灣,癌症已連續四十年蟬聯十大死因的首位。且癌症發生率也年年上升。癌症的傳統療法常具有同時傷害癌症細胞與一般細胞的性質,身體虛弱的癌症病患不僅需承受強大的副作用,且治療過程往往十分漫長。因此需要開發新型且有效的癌症治療方法。在醫學上,有使用細菌進行免疫反應之免疫療法。免疫療法是藉由活化人體的免疫系統,來達到殺傷癌細胞的效果。但癌症病患的體內常有抗生素與溶菌酶等其他療法所施打的藥物,導致微生物降低活性甚至死亡。因此科學家便致力研究結合微生物的生物複合材料,來增強生物細胞對環境的適應性。 本研究利用本實驗室於2015年發表於JACS之文章,利用類沸石咪唑骨架材料-90(ZIF-90)封裝酵素之技術,合成微米級ZIF-90封裝大腸桿菌(E .coli@ZIF-90),並與先前發表之多晶包覆大腸桿菌奈米級類沸石咪唑骨架材料-8(E. coli⸦ZIF-8)比較。發現經由紫外光滅菌程序,仍能保持單晶包覆之E . coli@ZIF-90內大腸桿菌約百分之八十的存活率。且在照射紫外光時間增加後,大腸桿菌之存活率沒有明顯下降。並合成封裝抗癌藥物之奈米級ZIF-90,期望將來可將抗癌藥物協同細菌癌症療法。以開創嶄新的癌症療法。zh_TW
dc.description.abstractCancer has remained the leading cause of death in Taiwan, with rising incidence rates annually. Conventional cancer treatments pose risks to both cancer cells and healthy cells, resulting in severe side effects and lengthy procedures for weakened patients. Microbial-mediated treatments provide a targeted approach by selectively colonizing tumors, inhibiting cancerous growth, and minimizing negative impacts compared to less precise methods. However, concerns arise regarding the potential spread, mutation, and acquisition of antibiotic resistance by attenuated bacteria. Enhancing targeting efficiency and identifying safe and effective bacterial strains continue to pose challenges in this field. According to our previous report, in this study, our laboratory successfully synthesized micron-scale Zeolitic imidazolate frameworks-90 (ZIF-90)-encapsulated E. coli (E. coli@ZIF-90). To make comparisons, we examined the poly-nanocrystalline encapsulated E. coli known as Zeolitic imidazolate frameworks -8 (E. coli⸦ZIF-8). Despite increased exposure to UV light, the single-crystal coated E. coli@ZIF-90 displayed an impressive 80% survival rate of encapsulated bacteria, showcasing exceptional preservation during UV sterilization with no significant decline in E. coli′s survival rate. Furthermore, our research successfully synthesized nanoscale ZIF-90 for the encapsulation of anti-cancer drugs, demonstrating the potential for synergistic approaches that integrate anti-cancer drugs and bacterial cancer therapy, paving the way for a novel paradigm in cancer treatment with enhanced therapeutic outcomes.en_US
DC.subject金屬有機框架zh_TW
DC.subject微生物介導療法zh_TW
DC.subjectZeta 電位zh_TW
DC.subject大腸桿菌zh_TW
DC.subject植物乳桿菌B21zh_TW
DC.subjectMetal-organic Frameworksen_US
DC.subjectMicrobial-Mediated Therapyen_US
DC.subjectZeta Potentialen_US
DC.subjectEscherichia colien_US
DC.subjectLactiplantibacillus plantarum B21en_US
DC.title單晶金屬有機骨架材料封裝活體細菌之研究zh_TW
dc.language.isozh-TWzh-TW
DC.titleBacterial Microrobot for the Encapsulation of Living Bacteria in a Single Metal-Organic Frameworksen_US
DC.type博碩士論文zh_TW
DC.typethesisen_US
DC.publisherNational Central Universityen_US

若有論文相關問題,請聯絡國立中央大學圖書館推廣服務組 TEL:(03)422-7151轉57407,或E-mail聯絡  - 隱私權政策聲明